Cagrilintide
Metabolic & Weight ManagementLong-acting amylin analog that reduces appetite and slows gastric emptying, being studied for weight loss.
Key Benefits
- ✓Reduced appetite
- ✓Slows gastric emptying
- ✓Enhanced weight loss
- ✓Complements GLP-1 agonists
- ✓Improved satiety
- ✓Better blood sugar control
Dosing Information
Detailed Protocol
Administered via subcutaneous injection. In clinical trials, dosed weekly. Being studied in combination with semaglutide (CagriSema).
About Cagrilintide
Cagrilintide is a long-acting amylin analog being developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin that regulates appetite and gastric emptying. Cagrilintide is being studied in combination with semaglutide for enhanced weight loss.
Research Notes
Phase 3 trials ongoing. CagriSema (combination with semaglutide) shows enhanced weight loss beyond semaglutide alone, reaching 25%+ weight reduction in trials.
Potential Side Effects
- •Nausea
- •Vomiting
- •Diarrhea
- •Injection site reactions
Always consult with a healthcare professional before starting any peptide therapy.